Roman Groisberg1, Jason Roszik2, Anthony Conley3, Shreyaskumar R Patel3, Vivek Subbiah4. 1. Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA. 2. Departments of Melanoma Medical Oncology and Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA. 3. Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA. 4. Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Unit 455, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA. vsubbiah@mdanderson.org.
Abstract
PURPOSE OF REVIEW: Sarcomas are rare, heterogeneous group of soft tissue and bone tumors. Precise diagnosis of specific subtypes is challenging using conventional methods. Herein, we review the role of next-generation sequencing (NGS) technology that is used for rapid sequencing of DNA and RNA. RECENT FINDINGS: Recent sarcoma specific studies recommend that molecular genetic testing should be added at diagnosis for appropriate clinical management in addition to diagnosis by expert pathologists. NGS has already been used to identify potentially actionable mutations, copy number alterations, and gene fusions. Rationally, choosing a drug based on an individual patient profile aka: "precision oncology" has been so far limited to few case reports in sarcomas. As we improve our ability to deliver personalized medicine using all modalities including conventional therapy, more patients may eventually benefit. As the cost and capacity of NGS outpace Moore's law, so does the probability of success.
PURPOSE OF REVIEW: Sarcomas are rare, heterogeneous group of soft tissue and bone tumors. Precise diagnosis of specific subtypes is challenging using conventional methods. Herein, we review the role of next-generation sequencing (NGS) technology that is used for rapid sequencing of DNA and RNA. RECENT FINDINGS: Recent sarcoma specific studies recommend that molecular genetic testing should be added at diagnosis for appropriate clinical management in addition to diagnosis by expert pathologists. NGS has already been used to identify potentially actionable mutations, copy number alterations, and gene fusions. Rationally, choosing a drug based on an individual patient profile aka: "precision oncology" has been so far limited to few case reports in sarcomas. As we improve our ability to deliver personalized medicine using all modalities including conventional therapy, more patients may eventually benefit. As the cost and capacity of NGS outpace Moore's law, so does the probability of success.
Authors: George Jour; John D Scarborough; Robin L Jones; Elizabeth Loggers; Seth M Pollack; Colin C Pritchard; Benjamin L Hoch Journal: Hum Pathol Date: 2014-04-24 Impact factor: 3.466
Authors: Vivek Subbiah; Christian Meyer; Ralph Zinner; Funda Meric-Bernstam; Marianna L Zahurak; Ashley O'Connor; Jason Roszik; Kenna Shaw; Joseph A Ludwig; Razelle Kurzrock; Nilofer A Azad Journal: Clin Cancer Res Date: 2017-04-04 Impact factor: 12.531
Authors: Jennifer A Perry; Adam Kiezun; Peter Tonzi; Eliezer M Van Allen; Scott L Carter; Sylvan C Baca; Glenn S Cowley; Ami S Bhatt; Esther Rheinbay; Chandra Sekhar Pedamallu; Elena Helman; Amaro Taylor-Weiner; Aaron McKenna; David S DeLuca; Michael S Lawrence; Lauren Ambrogio; Carrie Sougnez; Andrey Sivachenko; Loren D Walensky; Nikhil Wagle; Jaume Mora; Carmen de Torres; Cinzia Lavarino; Simone Dos Santos Aguiar; Jose Andres Yunes; Silvia Regina Brandalise; Gabriela Elisa Mercado-Celis; Jorge Melendez-Zajgla; Rocío Cárdenas-Cardós; Liliana Velasco-Hidalgo; Charles W M Roberts; Levi A Garraway; Carlos Rodriguez-Galindo; Stacey B Gabriel; Eric S Lander; Todd R Golub; Stuart H Orkin; Gad Getz; Katherine A Janeway Journal: Proc Natl Acad Sci U S A Date: 2014-12-15 Impact factor: 11.205
Authors: Yunyun Jiang; Vivek Subbiah; Filip Janku; Joseph A Ludwig; Aung Naing; Robert S Benjamin; Robert E Brown; Pete Anderson; Razelle Kurzrock Journal: PLoS One Date: 2014-08-13 Impact factor: 3.240
Authors: Roman Groisberg; David S Hong; Vijaykumar Holla; Filip Janku; Sarina Piha-Paul; Vinod Ravi; Robert Benjamin; Shreyas Kumar Patel; Neeta Somaiah; Anthony Conley; Siraj M Ali; Alexa B Schrock; Jeffrey S Ross; Philip J Stephens; Vincent A Miller; Shiraj Sen; Cynthia Herzog; Funda Meric-Bernstam; Vivek Subbiah Journal: Oncotarget Date: 2017-06-13
Authors: Vivek Subbiah; Shannon N Westin; Kai Wang; Dejka Araujo; Wei-Lien Wang; Vincent A Miller; Jeffrey S Ross; Phillip J Stephens; Gary A Palmer; Siraj M Ali Journal: J Hematol Oncol Date: 2014-01-14 Impact factor: 17.388
Authors: Roman Groisberg; David S Hong; Jason Roszik; Filip Janku; Apostolia M Tsimberidou; Milind Javle; Funda Meric-Bernstam; Vivek Subbiah Journal: Mol Cancer Ther Date: 2018-04-13 Impact factor: 6.261
Authors: Anthony P Conley; Wei-Lien Wang; John A Livingston; Vinod Ravi; Jen-Wei Tsai; Ali Ali; Davis R Ingram; Caitlin D Lowery; Christina L Roland; Neeta Somaiah; Patrick Hwu; Cassian Yee; Vivek Subbiah; Andrew Futreal; Alexander J Lazar; Shreyaskumar Patel; Jason Roszik Journal: Cancers (Basel) Date: 2019-05-15 Impact factor: 6.639